TaiMed Biologics Inc (中裕新藥) plans to apply within a month to the US Food and Drug Administration (FDA) for permission to license its Trogarzo “by intravenous push” treatment, as the company’s phase 3 clinical trial showed promising results, it said in a filing with the Taipei Exchange on Sunday.
On March 1, 2019, the HIV/AIDS drug developer began its last stage of human testing in the US to observe whether Trogarzo by intravenous push could produce the same effect as its Trogarzo “by intravenous infusion” treatment, which has already been launched.
Trogarzo by intravenous infusion needs to be diluted with saline solution and administration of the medication takes 15 minutes, while Trogarzo by intravenous push can be given to patients undiluted and takes only 30 seconds to administer, the company said.
Twenty-two people who were infected with HIV-1, but were in a stable condition and had already taken Trogarzo by intravenous infusion for at least three months, participated in the phase 3 trial, TaiMed said in the filing.
Participants initially took Trogarzo by intravenous infusion once every two weeks, but later took Trogarzo by intravenous push, also once every two weeks, the company said.
They did not report any severe adverse reactions, but some had mild or medium adverse reactions, it said.
The concentration of Trogarzo declined at similar rates in participants treated using the intravenous infusion and intravenous push methods, indicating that the different administration routes did not affect the rate of the drugs’ absorption, TaiMed said.
The different methods of administration did not lead to a change in participants’ viral loads, and no one reported viral loads of more than than 1,000 copies per milliliter twice consecutively, it said.
Meanwhile, no participants developed anti-Trogarzo antibodies, TaiMed said.
“Overall, the test results have reached our objectives. We will apply for a biologics license,” TaiMed said. “It is expected that we will obtain approval within a few months.”
TaiMed paid about US$2 million for the phase 3 clinical trail, which was carried out by a contract research organization, it said, adding that the payment excluded drug expenses and research costs.
The company said it expects to receive a milestone payment of US$3 million from its marketing and distribution partner, Theratechnologies Inc, if it gains approval from the FDA.
TaiMed has signed a 12-year contract with Theratechnologies, which would be in charge of sales of Trogarzo by intravenous push in the US, Canada, most European countries and Israel.
It has signed another contract with Meroven Ltd, which would market the medication in the Middle East and North Africa.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s biggest contract chipmaker, booked its first-ever profit from its Arizona subsidiary in the first half of this year, four years after operations began, a company financial statement showed. Wholly owned by TSMC, the Arizona unit contributed NT$4.52 billion (US$150.1 million) in net profit, compared with a loss of NT$4.34 billion a year earlier, the statement showed. The company attributed the turnaround to strong market demand and high factory utilization. The Arizona unit counts Apple Inc, Nvidia Corp and Advanced Micro Devices Inc among its major customers. The firm’s first fab in Arizona began high-volume production
VOTE OF CONFIDENCE: The Japanese company is adding Intel to an investment portfolio that includes artificial intelligence linchpins Nvidia Corp and TSMC Softbank Group Corp agreed to buy US$2 billion of Intel Corp stock, a surprise deal to shore up a struggling US name while boosting its own chip ambitions. The Japanese company, which is adding Intel to an investment portfolio that includes artificial intelligence (AI) linchpins Nvidia Corp and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), is to pay US$23 a share — a small discount to Intel’s last close. Shares of the US chipmaker, which would issue new stock to Softbank, surged more than 5 percent in after-hours trading. Softbank’s stock fell as much as 5.4 percent on Tuesday in Tokyo, its
COLLABORATION: Softbank would supply manufacturing gear to the factory, and a joint venture would make AI data center equipment, Young Liu said Hon Hai Precision Industry Co (鴻海精密) would operate a US factory owned by Softbank Group Corp, setting up what is in the running to be the first manufacturing site in the Japanese company’s US$500 billion Stargate venture with OpenAI and Oracle Corp. Softbank is acquiring Hon Hai’s electric-vehicle plant in Ohio, but the Taiwanese company would continue to run the complex after turning it into an artificial intelligence (AI) server production plant, Hon Hai chairman Young Liu (劉揚偉) said yesterday. Softbank would supply manufacturing gear to the factory, and a joint venture between the two companies would make AI data
The prices of gasoline and diesel at domestic fuel stations are to rise NT$0.1 and NT$0.4 per liter this week respectively, after international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) announced yesterday. Effective today, gasoline prices at CPC and Formosa stations are to rise to NT$27.3, NT$28.8 and NT$30.8 per liter for 92, 95 and 98-octane unleaded gasoline respectively, the companies said in separate statements. The price of premium diesel is to rise to NT$26.2 per liter at CPC stations and NT$26 at Formosa pumps, they said. The announcements came after international crude oil prices
RSS